FDA recommended today: "To reduce the potential for gadolinium accumulation, health care professionals should consider limiting gadolinium-based contrast agents(GBCA) use to clinical circumstances in which the additional information provided by the contrast is necessary. Health care professionals are also urged to reassess the necessity of repetitive GBCA MRIs in established treatment protocols."

http://www.fda.gov/Drugs/DrugSafety/ucm455386.htm